Compelling study reinforcing the value of LTCG’s cognitive screening tool featured at Alzheimer’s Association’s International Conference

Eden Prairie, MN – October 22, 2014 – LTCG, the recognized leader in business process outsourcing for long term care insurance, presented a recent study which further demonstrates the value of its proprietary Minnesota Cognitive Acuity Screen (MCAS) at the 2014 Alzheimer’s Association’s International Conference. Dr. Geoffrey Tremont, associate professor of psychiatry at Brown University and director of neuropsychology at Rhode Island Hospital and The Miriam Hospital, shared impressive results from the Brown University study, which utilized specific data collected through a portion of the MCAS to determine whether it could accurately predict an individual’s future risk of developing Alzheimer’s disease. The poster presentation was made to an international audience that gathered in Copenhagen, Denmark, to discuss the latest worldwide dementia research.

The MCAS is a highly accurate assessment tool administered via telephonic or in-person screenings. It is used to detect early cognitive impairment, even before physical symptoms begin to manifest in many cases. Researchers administered the tool to healthy adults ages 55 to 75 enrolled within a larger study of older adults that had a family history of Alzheimer’s disease. Study findings revealed that performance on a key MCAS subtest was closely associated with the level of underlying cortical beta amyloid burden, a plaque buildup in the cerebral cortex that results from the degeneration of tissue—and an important indicator of cognitive decline.

“These findings indicate that the MCAS has strong potential in helping to identify people who have a higher risk of developing Alzheimer’s disease later in life,” said Dr. Stephen Holland, Chief Medical Officer of LTCG. “This study also confirms our assertion that the MCAS is an incredibly powerful tool for detecting cognitive impairment at a very early stage.”

In addition to its role as a tool used in research studies like the one shared at this year’s Alzheimer’s conference, the MCAS is leveraged by leading insurers to detect cognitive risk through the underwriting process, as well as to determine benefit eligibility at the point of a claim submission for long term care insurance. To date, it has been administered to more than 1,000,000 individuals nationwide.

About LTCG

LTCG is the leading provider of administrative solutions and clinical services to the long term care insurance industry, with nearly two decades of experience in this space. LTCG currently manages over 1.3 million policies and serves more than 50 carriers nationwide. The company addresses all types of customer needs and policy requirements—from application processing and underwriting of new business to claims and administration of open and closed blocks. LTCG’s advanced data analytics, actuarial and risk management capabilities and unmatched industry expertise can help organizations manage their business and develop emerging products such as hybrid life/long term care policies. In addition, LTCG provides clients with unique insight about risk management built upon the industry’s largest database of long term care underwriting and claims outcomes. For more information, visit

About LTCG’s industry-leading MCAS tool

The MCAS was developed and statistically validated in a 1999 blinded trial by a team of physicians and scientists, as well as in University-based blinded trials each year since 2009. Ongoing research at Brown University and a growing body of peer-reviewed literature has validated the MCAS’ ability to detect mild cognitive impairment, early dementia, functional decline and excess mortality. And, the MCAS has been selected both for use in the Brown University’s National Institute of Health Alzheimer’s Disease Prevention Trial and as the new screening tool for the National Institute of Health’s Alzheimer’s Disease Registry. In addition, LTCG’s MCAS has been featured in a large number of peer reviewed scientific publications and presented at a number of international scientific meetings.

About The Alzheimer’s Association’s International Conference

The Alzheimer’s Association’s International Conference is held annually to discuss cutting-edge research and technology about the prevention and treatment of Alzheimer’s and other forms of dementia. The next conference will occur on July 18-23, 2015 in Washington, D.C.


Adam Hoffman